Clinical Research Directory

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future. This is a Phase III trial. It will take place in multiple locations and will follow a double-blind, randomized, placebo-controlled clinical design, meaning neither doctors nor participants will know whether they receive EA-230 or placebo during the trial. Assignment to EA-230 or placebo occurs by chance, like throwing dice. The total duration of the trial, including medical check-ups, will be approximately 71 days. There is a total of 10 visits, including a screening-, a pre-operative-, and 2 remote visits. 7 of these visits are during your stay at the hospital.

VR During Chest Tube Removal After CABG

The purpose of this randomized controlled clinical trial was to investigate whether virtual reality (VR) could reduce pain and anxiety during chest tube removal in adult patients who underwent coronary artery bypass graft (CABG) surgery. The main questions this study aimed to answer were: * Does the use of virtual reality reduce pain during chest tube removal? * Does the use of virtual reality reduce anxiety and improve physiological responses during chest tube removal? Researchers compared patients who received virtual reality in addition to routine care with patients who received routine care alone. A total of 82 patients participated in the study. Participants were randomly assigned to two groups, with 41 patients in each group. Participants in the virtual reality group: * Wore a VR headset and watched nature videos with accompanying sounds, starting five minutes before chest tube removal and continuing throughout the procedure. * Received routine care during chest tube removal. Participants in the control group: \- Received routine care during chest tube removal without virtual reality. Pain, anxiety, and physiological parameters were assessed before and after chest tube removal to evaluate the effects of the intervention.